Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Publication date: January 2021Source: The Lancet Haematology, Volume 8, Issue 1Author(s): Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Fredette Hita, Jason Valent, Michael Rosenzweig, Jeffrey A Zonder, Madhav Dhodapkar, Natalie Callander, Todd Zimmerman, Peter M Voorhees, Brian Durie, S Vincent Rajkumar, Paul G Richardson, Robert Z Orlowski, SWOG1211 Trial Investigators
Source: The Lancet Haematology - Category: Hematology Source Type: research